SCHEMBL301797

SCHEMBL301797

CCCc1ccccc1S(N)(=O)=O

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA2 P00918 14/20 0.47
CA1 P00915 11/20 0.47
CA9 Q16790 7/20 0.47
CA6 P23280 3/20 0.47
CA5A P35218 3/20 0.47
CA12 O43570 3/20 0.47
CA4 P22748 2/20 0.47
CA7 P43166 2/20 0.47
CA5B Q9Y2D0 2/20 0.47
CYP2C9 P11712 1/20 0.47
CA14 Q9ULX7 1/20 0.47
PTGES2 Q9H7Z7 3/20 0.42
CTSB P07858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
METAP2 P50579 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7362559 0.98 CA2 (0.45) CA2CA1CA9CA6CA5A
Ammonia Solution, Strong SCHEMBL28150872 0.98 CA2 (0.45) CA2CA1CA9CA6CA5A
Hydrochloric Acid SCHEMBL12481385 0.98 CA2 (0.45) CA2CA1CA9CA6CA5A
SCHEMBL30140890 0.89 CA2 (0.49) CA2CA1CA9CA6CA5A
SCHEMBL51728 0.89 CA2 (0.49) CA2CA1CA9CA6CA5A
SCHEMBL8349565 0.87 CA2 (0.54) CA2CA1CA9CA6CA5A
SCHEMBL1881549 0.87 CA2 (0.50) CA2CA1CA9CA6CA5A
Ammonia Solution, Strong SCHEMBL28168503 0.87 CA2 (0.47) CA2CA1CA9CA6CA5A
Methane SCHEMBL27933205 0.87 CA2 (0.47) CA2CA1CA9CA6CA5A
SCHEMBL7444688 0.87 CA2 (0.47) CA2CA1CA9CA6CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2026-01-22 US claimed
CN-113227036-A Ethylenediamine compound and application thereof 中国人民解放军军事科学院军事医学研究院 2021-08-06 CN claimed
CN-108440856-A Dye-colored body and method for producing same 谦华科技股份有限公司 2018-08-24 CN claimed
EP-3329047-A1 CHEMICAL COMPOSITION FOR ANTI-CORROSION MINERAL PAPER Cheng Kit Yew, Nelson (SG) 2018-06-06 EP claimed
CN-103588697-B Disubstituted benzenes sulfamide compound of one class 2,5 and its production and use 中国科学院上海药物研究所 2017-09-15 CN claimed
CN-106588742-A Pyroglutamic acid-derived hydrogen-bonding organic catalyst and its preparation method and application 中南大学 2017-04-26 CN claimed
JP-4851328-B2 2012-01-11 JP claimed
EP-1976498-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-10-08 EP claimed
US-20080207588-A1 Spiro-Heterocyclic Chromans, Thiochromans and Dihydroquinolines CHU DANIEL T W 2008-08-28 US claimed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 WO claimed
JP-2007506692-A 2007-03-22 JP claimed
EP-1670470-A1 PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2006-06-21 EP claimed
WO-2006047774-A1 MULTILAYERED PIPES COMPRISING HYDROLYSIS RESISTANT POLYAMIDES E.I. DUPONT DE NEMOURS AND COMPANY (US) 2006-05-04 WO claimed
WO-2006047776-A2 MARINE UMBILICAL COMPRISING HYDROLYSIS RESISTANT POLYAMIDES E.I. DUPONT DE NEMOURS AND COMPANY (US) 2006-05-04 WO claimed
EP-1648896-A1 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES FERRER INTERNACIONAL, S.A. (ES) 2006-04-26 EP claimed
WO-2005030209-A1 PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2005-04-07 WO claimed
WO-2005014596-A1 7-SUBSTITUTED 3-NITRO-PYRAZOLO `1,5-A! PYRIMIDINES FERRER INTERNACIONAL, S.A. (ES) 2005-02-17 WO claimed
EP-1165866-B1 ABRASIVE FILAMENTS OF PLASTICIZED POLYAMIDES DU PONT (US) 2004-01-28 EP claimed
EP-1283832-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP claimed
WO-2001090092-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207588-A1 Spiro-Heterocyclic Chromans, Thiochromans and Dihydroquinolines CBR3, CBR1, DHRS9 CA2 3822/4885CA1 4074/4885CA9 672/4885
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS CNR1, CDR2, SMN1; SMN2 CA2 240/4885CA1 93/4885CA9 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.